eoadjuvant docetaxel in high-risk prostate cancer

Phase 2

Recruiting

• Conditions: prostate cancer; prostate cancer, high-risk

• Registration Number: JPRN-jRCTs021180009
• Lead Sponsor: arita Shintaro

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-25
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 150

Inclusion Criteria

pathologically diagnosed high-risk prostate cancer who have a plan to receive surgical treatment

Exclusion Criteria

.Inappropriate patients for this study judged by the physicians

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
surgical CR rate

Secondary Outcome Measures

Name	Time	Method
biochemical recurrence, cancer specific survival, overall survival, adverse event